Alysa Guffey writes business and development stories for IndyStar
There are four GLP-1 FDA decisions to watch in 2026 Eli Lillys injectable Mounjaro, with a new indication to reduce the risk of major adverse cardiovascular events in patients with T2DM, is expected in mid-2026
The transcriptional activity, protein expression, and resultant metabolic output of a microbial community can be discordant with its genomic profile due to post-transcriptional regulation, environmental cues, substrate availability, and host-microbe interactions
Three Warning Letters in Six Months The March 2026 letter is the third FDA warning to Novo Nordisk in six months
Why Gradual Titration Improves Your Outcomes Slow dose escalation allows your gastrointestinal tract and appetite-regulating pathways to acclimate gradually rather than experiencing a sudden shock to the system
Retail price is the price at which pharmacies sell medications to patients